ATR

Business Context and Reporting Period

Company: AptarGroup, Inc. (ATR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Aptar is a global leader in drug and consumer product dosing, dispensing, and protection technologies. The company operates through three reporting segments: Pharma (prescription drug, consumer health care, injectables), Beauty (fragrance, skincare, personal care), and Closures (food, beverage, personal care). Headquartered in Crystal Lake, Illinois, Aptar employs approximately 14,000 people across 20 countries.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Reported sales increased 5% driven by a 2% positive currency translation impact and 1% from acquisitions. Core sales (excluding currency and acquisitions) grew 2%.
• Segment Performance:
  • Pharma: Sales up 6% (Core +3%). Driven by strong volume growth in prescription drug and injectables (GLP-1 components), offset by a decline in consumer health care.
  • Beauty: Sales up 7% (Core +2%). Growth driven by tooling sales and personal care, though Adjusted EBITDA margin declined to 12.1% from 13.0% due to product mix and tariff costs.
  • Closures: Sales up 2% (Core +1%). Beverage and food markets showed growth, while personal care declined.
• Acquisitions:
  • Sommaplast: Acquired 100% equity for $27.0 million (net) in December 2025 to expand oral dosing pharma packaging.
  • BTY: Increased ownership to 80% for approximately $29.0 million in July 2025, resulting in a $26.5 million gain from remeasurement of the previously held equity interest.
• Debt Structure: Issued $600.0 million in 4.75% Senior Notes due 2031 and repaid $125.0 million of 3.6% Senior Notes. Interest expense increased to $52.7 million from $43.9 million.
• Shareholder Returns: Returned $485.8 million to shareholders via dividends ($120.8 million) and share repurchases ($365.0 million).

Guidance, Outlook, and Risks

• 2026 Q1 Guidance: Management expects diluted earnings per share in the range of $1.13 to $1.21, excluding restructuring, fair value changes, and acquisition costs. This assumes an effective tax rate of 21% to 23%.
• Capital Expenditures: Expected to be in the range of $260.0 million to $280.0 million for 2026.
• Key Risks:
  • Geopolitical & Trade: Tariffs imposed by the U.S. on imports from China, Canada, and Mexico have increased raw material costs and created supply chain uncertainty.
  • Legal Proceedings: Ongoing litigation includes patent infringement actions by Nemera (ophthalmic products) and antitrust/trade secret disputes with ARS Pharmaceuticals.
  • Goodwill Impairment: Approximately $1.08 billion in recorded goodwill. The Beauty reporting unit required a quantitative impairment test due to unfavorable circumstances, though no impairment was recognized.
  • Regulatory: Evolving environmental regulations (e.g., EU Packaging and Packaging Waste Regulation) and PFAS bans may require product reformulation.

Investor Verification Checklist

• Debt Servicing: Verify the impact of the new $600M 4.75% notes on future interest coverage ratios given the rise in interest expense.
• Beauty Segment Margins: Monitor the Beauty segment's Adjusted EBITDA margin (down to 12.1%) to ensure tariff pass-throughs and mix shifts do not persistently erode profitability.
• Acquisition Integration: Assess the integration progress and synergy realization of the BTY and Sommaplast acquisitions.
• Legal Exposure: Track the status of the Nemera patent litigation and ARS antitrust/trade secret claims for potential financial impact.
• Goodwill Valuation: Review the assumptions used in the Beauty reporting unit's goodwill impairment test (revenue growth, EBITDA margins, discount rate) given the narrow margin of safety.